Director Makes Bold Move With Major Stock Purchase in Zentalis Pharmaceuticals
Pleasing Signs As A Number Of Insiders Buy Zentalis Pharmaceuticals Stock
Express News | Zentalis Pharmaceuticals Inc - Topline Data From Denali Part 2 Expected by Year End 2026
Express News | Zentalis Pharmaceuticals Announces First Patient Dosed in Denali Part 2 Clinical Trial of Azenosertib in Patients With Cyclin E1+ Proc
Express News | Zentalis Pharmaceuticals To Present Poster At 2025 ASCO Annual Meeting
Zentalis Pharmaceuticals Announces Poster Presentation at 2025 ASCO Annual Meeting
Express News | Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
TD Cowen Maintains Zentalis Pharmaceuticals(ZNTL.US) With Buy Rating
Wells Fargo Maintains Zentalis Pharmaceuticals(ZNTL.US) With Hold Rating, Maintains Target Price $6
Morgan Stanley Maintains Zentalis Pharmaceuticals(ZNTL.US) With Hold Rating, Maintains Target Price $8
Express News | Wedbush Reiterates Neutral on Zentalis Pharma, Maintains $4 Price Target
Analysts Conflicted on These Healthcare Names: Savara (SVRA) and Zentalis Pharmaceuticals (ZNTL)
Zentalis Pharmaceuticals Reports Progress and Financials
Stifel Maintains Zentalis Pharmaceuticals(ZNTL.US) With Buy Rating, Maintains Target Price $9
Stifel Nicolaus Sticks to Their Buy Rating for Zentalis Pharmaceuticals (ZNTL)
Promising Potential of Zentalis Pharmaceuticals' Azenosertib in Treating Platinum-Resistant Ovarian Cancer
Oppenheimer Remains a Buy on Zentalis Pharmaceuticals (ZNTL)
Zentalis Pharmaceuticals GAAP EPS of -$2.33 Beats by $0.13, Revenue of $67.43M Beats by $26.81M
12 Health Care Stocks Moving In Wednesday's After-Market Session